Design, Synthesis, and Actions of an Innovative Bispecific Designer Peptide

Laura M.G. Meems, Ingrid A. Andersen, Shuchong Pan, Gail Harty, Yang Chen, Ye Zheng, Gerald E. Harders, Tomoki Ichiki, Denise M. Heublein, Seethalakshmi R. Iyer, S Jeson Sangaralingham, Daniel J Mc Cormick, John C Jr. Burnett

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Despite optimal current therapies, cardiovascular disease remains the leading cause for death worldwide. Importantly, advances in peptide engineering have accelerated the development of innovative therapeutics for diverse human disease states. Additionally, the advancement of bispecific therapeutics targeting >1 signaling pathway represents a highly innovative strategy for the treatment of cardiovascular disease. We, therefore, engineered a novel, designer peptide, which simultaneously targets the pGC-A (particulate guanylyl cyclase A) receptor and the MasR (Mas receptor), potentially representing an attractive cardiorenoprotective therapeutic for cardiovascular disease. We engineered a novel, bispecific receptor activator, NPA7, that represents the fusion of a 22-amino acid sequence of BNP (B-type natriuretic peptide; an endogenous ligand of pGC-A) with Ang 1-7 (angiotensin 1-7)-the 7-amino acid endogenous activator of MasR. We assessed NPA7's dual receptor activating actions in vitro (second messenger production and receptor interaction). Further, we performed an intravenous peptide infusion comparison study in normal canines to study its biological actions in vivo, including in the presence of an MasR antagonist. Our in vivo and in vitro studies demonstrate the successful synthesis of NPA7 as a bispecific receptor activator targeting pGC-A and MasR. In normal canines, NPA7 possesses enhanced natriuretic, diuretic, systemic, and renal vasorelaxing and cardiac unloading properties. Importantly, NPA7's actions are superior to that of the individual native pGC-A or MasR ligands. These studies advance NPA7 as a novel, bispecific designer peptide with potential cardiorenal therapeutic benefit for the treatment of cardiovascular disease, such as hypertension and heart failure.

Original languageEnglish (US)
Pages (from-to)900-909
Number of pages10
JournalHypertension (Dallas, Tex. : 1979)
Volume73
Issue number4
DOIs
StatePublished - Apr 1 2019

Fingerprint

Peptides
Cardiovascular Diseases
Therapeutics
Canidae
Ligands
Brain Natriuretic Peptide
Second Messenger Systems
Diuretics
Intravenous Infusions
Cause of Death
Amino Acid Sequence
Heart Failure
Hypertension
Kidney
Amino Acids
atrial natriuretic factor receptor A
In Vitro Techniques

Keywords

  • angiotensin 1-7
  • cardiovascular disease
  • designer peptide
  • heart failure
  • hypertension
  • Mas receptor
  • natriuretic peptide

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Design, Synthesis, and Actions of an Innovative Bispecific Designer Peptide. / Meems, Laura M.G.; Andersen, Ingrid A.; Pan, Shuchong; Harty, Gail; Chen, Yang; Zheng, Ye; Harders, Gerald E.; Ichiki, Tomoki; Heublein, Denise M.; Iyer, Seethalakshmi R.; Sangaralingham, S Jeson; Mc Cormick, Daniel J; Burnett, John C Jr.

In: Hypertension (Dallas, Tex. : 1979), Vol. 73, No. 4, 01.04.2019, p. 900-909.

Research output: Contribution to journalArticle

Meems, LMG, Andersen, IA, Pan, S, Harty, G, Chen, Y, Zheng, Y, Harders, GE, Ichiki, T, Heublein, DM, Iyer, SR, Sangaralingham, SJ, Mc Cormick, DJ & Burnett, JCJ 2019, 'Design, Synthesis, and Actions of an Innovative Bispecific Designer Peptide', Hypertension (Dallas, Tex. : 1979), vol. 73, no. 4, pp. 900-909. https://doi.org/10.1161/HYPERTENSIONAHA.118.12012
Meems, Laura M.G. ; Andersen, Ingrid A. ; Pan, Shuchong ; Harty, Gail ; Chen, Yang ; Zheng, Ye ; Harders, Gerald E. ; Ichiki, Tomoki ; Heublein, Denise M. ; Iyer, Seethalakshmi R. ; Sangaralingham, S Jeson ; Mc Cormick, Daniel J ; Burnett, John C Jr. / Design, Synthesis, and Actions of an Innovative Bispecific Designer Peptide. In: Hypertension (Dallas, Tex. : 1979). 2019 ; Vol. 73, No. 4. pp. 900-909.
@article{aeb0c47a01a64117bbacedac7531275e,
title = "Design, Synthesis, and Actions of an Innovative Bispecific Designer Peptide",
abstract = "Despite optimal current therapies, cardiovascular disease remains the leading cause for death worldwide. Importantly, advances in peptide engineering have accelerated the development of innovative therapeutics for diverse human disease states. Additionally, the advancement of bispecific therapeutics targeting >1 signaling pathway represents a highly innovative strategy for the treatment of cardiovascular disease. We, therefore, engineered a novel, designer peptide, which simultaneously targets the pGC-A (particulate guanylyl cyclase A) receptor and the MasR (Mas receptor), potentially representing an attractive cardiorenoprotective therapeutic for cardiovascular disease. We engineered a novel, bispecific receptor activator, NPA7, that represents the fusion of a 22-amino acid sequence of BNP (B-type natriuretic peptide; an endogenous ligand of pGC-A) with Ang 1-7 (angiotensin 1-7)-the 7-amino acid endogenous activator of MasR. We assessed NPA7's dual receptor activating actions in vitro (second messenger production and receptor interaction). Further, we performed an intravenous peptide infusion comparison study in normal canines to study its biological actions in vivo, including in the presence of an MasR antagonist. Our in vivo and in vitro studies demonstrate the successful synthesis of NPA7 as a bispecific receptor activator targeting pGC-A and MasR. In normal canines, NPA7 possesses enhanced natriuretic, diuretic, systemic, and renal vasorelaxing and cardiac unloading properties. Importantly, NPA7's actions are superior to that of the individual native pGC-A or MasR ligands. These studies advance NPA7 as a novel, bispecific designer peptide with potential cardiorenal therapeutic benefit for the treatment of cardiovascular disease, such as hypertension and heart failure.",
keywords = "angiotensin 1-7, cardiovascular disease, designer peptide, heart failure, hypertension, Mas receptor, natriuretic peptide",
author = "Meems, {Laura M.G.} and Andersen, {Ingrid A.} and Shuchong Pan and Gail Harty and Yang Chen and Ye Zheng and Harders, {Gerald E.} and Tomoki Ichiki and Heublein, {Denise M.} and Iyer, {Seethalakshmi R.} and Sangaralingham, {S Jeson} and {Mc Cormick}, {Daniel J} and Burnett, {John C Jr.}",
year = "2019",
month = "4",
day = "1",
doi = "10.1161/HYPERTENSIONAHA.118.12012",
language = "English (US)",
volume = "73",
pages = "900--909",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Design, Synthesis, and Actions of an Innovative Bispecific Designer Peptide

AU - Meems, Laura M.G.

AU - Andersen, Ingrid A.

AU - Pan, Shuchong

AU - Harty, Gail

AU - Chen, Yang

AU - Zheng, Ye

AU - Harders, Gerald E.

AU - Ichiki, Tomoki

AU - Heublein, Denise M.

AU - Iyer, Seethalakshmi R.

AU - Sangaralingham, S Jeson

AU - Mc Cormick, Daniel J

AU - Burnett, John C Jr.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Despite optimal current therapies, cardiovascular disease remains the leading cause for death worldwide. Importantly, advances in peptide engineering have accelerated the development of innovative therapeutics for diverse human disease states. Additionally, the advancement of bispecific therapeutics targeting >1 signaling pathway represents a highly innovative strategy for the treatment of cardiovascular disease. We, therefore, engineered a novel, designer peptide, which simultaneously targets the pGC-A (particulate guanylyl cyclase A) receptor and the MasR (Mas receptor), potentially representing an attractive cardiorenoprotective therapeutic for cardiovascular disease. We engineered a novel, bispecific receptor activator, NPA7, that represents the fusion of a 22-amino acid sequence of BNP (B-type natriuretic peptide; an endogenous ligand of pGC-A) with Ang 1-7 (angiotensin 1-7)-the 7-amino acid endogenous activator of MasR. We assessed NPA7's dual receptor activating actions in vitro (second messenger production and receptor interaction). Further, we performed an intravenous peptide infusion comparison study in normal canines to study its biological actions in vivo, including in the presence of an MasR antagonist. Our in vivo and in vitro studies demonstrate the successful synthesis of NPA7 as a bispecific receptor activator targeting pGC-A and MasR. In normal canines, NPA7 possesses enhanced natriuretic, diuretic, systemic, and renal vasorelaxing and cardiac unloading properties. Importantly, NPA7's actions are superior to that of the individual native pGC-A or MasR ligands. These studies advance NPA7 as a novel, bispecific designer peptide with potential cardiorenal therapeutic benefit for the treatment of cardiovascular disease, such as hypertension and heart failure.

AB - Despite optimal current therapies, cardiovascular disease remains the leading cause for death worldwide. Importantly, advances in peptide engineering have accelerated the development of innovative therapeutics for diverse human disease states. Additionally, the advancement of bispecific therapeutics targeting >1 signaling pathway represents a highly innovative strategy for the treatment of cardiovascular disease. We, therefore, engineered a novel, designer peptide, which simultaneously targets the pGC-A (particulate guanylyl cyclase A) receptor and the MasR (Mas receptor), potentially representing an attractive cardiorenoprotective therapeutic for cardiovascular disease. We engineered a novel, bispecific receptor activator, NPA7, that represents the fusion of a 22-amino acid sequence of BNP (B-type natriuretic peptide; an endogenous ligand of pGC-A) with Ang 1-7 (angiotensin 1-7)-the 7-amino acid endogenous activator of MasR. We assessed NPA7's dual receptor activating actions in vitro (second messenger production and receptor interaction). Further, we performed an intravenous peptide infusion comparison study in normal canines to study its biological actions in vivo, including in the presence of an MasR antagonist. Our in vivo and in vitro studies demonstrate the successful synthesis of NPA7 as a bispecific receptor activator targeting pGC-A and MasR. In normal canines, NPA7 possesses enhanced natriuretic, diuretic, systemic, and renal vasorelaxing and cardiac unloading properties. Importantly, NPA7's actions are superior to that of the individual native pGC-A or MasR ligands. These studies advance NPA7 as a novel, bispecific designer peptide with potential cardiorenal therapeutic benefit for the treatment of cardiovascular disease, such as hypertension and heart failure.

KW - angiotensin 1-7

KW - cardiovascular disease

KW - designer peptide

KW - heart failure

KW - hypertension

KW - Mas receptor

KW - natriuretic peptide

UR - http://www.scopus.com/inward/record.url?scp=85062825671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062825671&partnerID=8YFLogxK

U2 - 10.1161/HYPERTENSIONAHA.118.12012

DO - 10.1161/HYPERTENSIONAHA.118.12012

M3 - Article

C2 - 30798663

AN - SCOPUS:85062825671

VL - 73

SP - 900

EP - 909

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 4

ER -